Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label trial of azenosertib versus investigator's choice chemotherapy in cyclin E1-positive platinum-resistant high-grade serous ovarian, primary peritoneal, or fallopian tube cancer
MOH_2026-08-11_016977Phase 3Not yet recruiting
- Sponsor
- K-Group Beta, Inc.
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azenosertib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by K-Group Beta, Inc. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
azenosertib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on MOH_2026-08-11_016977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-11_016977.